ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.331,39
0,00%
S&P 500
5.469,30
0,39%
US Dollar vs BRL
5,45241
0,00%
Bitcoin
61.375,84
-0,70%
Brent Oil
84,705
0,62%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. 4D Pharma PLC (LBPS)

  7. 4D Pharma PLC (LBPS) Notícias

LBPS

4D Pharma (LBPS)

4D Pharma PLC
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LBPS
DataHoraFonteTítuloCódigoCompanhia
03/01/202314:10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
19/07/202212:49Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:LBPS4D Pharma PLC
28/06/202214:50Business Wire4D pharma plc (“4D pharma”) Receives Notice of Delisting From NasdaqNASDAQ:LBPS4D Pharma PLC
27/06/202209:15TipRanksWhat Made Chardan Capital Downgrade 4d Pharma’s Stock?NASDAQ:LBPS4D Pharma PLC
24/06/202216:32TipRanksLadenburg Thalmann & Co. Downgrades 4d Pharma (LBPS) to HoldNASDAQ:LBPS4D Pharma PLC
24/06/202215:41Business WireUpdate on Suspension of TradingNASDAQ:LBPS4D Pharma PLC
26/05/202218:30Business Wire4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:LBPS4D Pharma PLC
19/05/202217:30Business Wire4D pharma to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:LBPS4D Pharma PLC
17/05/202208:00Business Wire4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International ConferenceNASDAQ:LBPS4D Pharma PLC
29/04/202207:34Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LBPS4D Pharma PLC
31/03/202218:27Business Wire4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022NASDAQ:LBPS4D Pharma PLC
28/03/202218:29Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:LBPS4D Pharma PLC
23/03/202208:00Business Wire4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell CarcinomaNASDAQ:LBPS4D Pharma PLC
02/03/202219:26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:LBPS4D Pharma PLC
28/02/202218:34Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:LBPS4D Pharma PLC
23/02/202209:00Business Wire4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines SummitNASDAQ:LBPS4D Pharma PLC
22/02/202209:00Business Wire4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s DiseaseNASDAQ:LBPS4D Pharma PLC
18/02/202219:03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LBPS4D Pharma PLC
18/02/202219:02Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:LBPS4D Pharma PLC
28/01/202208:45TipRanksLadenburg Thalmann & Co. Thinks 4d Pharma’s Stock is Going to RecoverNASDAQ:LBPS4D Pharma PLC
27/01/202209:00Business Wire4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of AsthmaNASDAQ:LBPS4D Pharma PLC
20/01/202209:00Business Wire4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004NASDAQ:LBPS4D Pharma PLC
20/01/202208:45TipRanksLadenburg Thalmann & Co. Maintains a Buy Rating on 4d Pharma (LBPS)NASDAQ:LBPS4D Pharma PLC
05/01/202209:00Business Wire4D pharma to Present at the H.C. Wainwright BioConnect ConferenceNASDAQ:LBPS4D Pharma PLC
03/01/202209:00Business Wire4D pharma appoints John Doyle as Chief Financial OfficerNASDAQ:LBPS4D Pharma PLC
13/12/202109:00Business Wire4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of AsthmaNASDAQ:LBPS4D Pharma PLC
09/12/202109:00Business Wire4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021NASDAQ:LBPS4D Pharma PLC
15/11/202110:00GlobeNewswire Inc.CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of DirectorsNASDAQ:LBPS4D Pharma PLC
11/11/202109:00Business Wire4D pharma to Participate in Jefferies London Healthcare ConferenceNASDAQ:LBPS4D Pharma PLC
12/10/202108:00Business Wire4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics SummitNASDAQ:LBPS4D Pharma PLC
 Apresentando as notícias mais relevantes sobre:NASDAQ:LBPS

Seu Histórico Recente

EU
0559T
0559T
LSE
50AH
Blitzen Sec.62f
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados